Navigation Links
NephroGenex Announces the Successful Completion of PYR-210
Date:11/7/2011

RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2011 /PRNewswire/ -- NephroGenex, Inc., a privately held drug development company, today announced the completion of PYR-210, a Phase 2b trial that studied the safety and efficacy of its lead drug candidate Pyridorin™ (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt nephropathy. 

PYR-210 evaluated two doses of Pyridorin™ against placebo in 317 patients over a one year treatment period. Patients enrolled in the trial were type 2 diabetic patients with elevated serum creatinine (SCr) levels and significant proteinuria, and were on standard of care which included adequate blood pressure control and a stable regimen of ACEi/ARB therapy. Efficacy was evaluated based on a 12 month change in SCr from baseline.    

As reported in the current online issue of the Journal of the American Society of Nephrology, Pyridorin™ was well tolerated and has a benign safety profile. Pyridorin™ did not produce a significant treatment effect in the entire patient population treated; however, in patients with less severe disease (i.e. baseline SCr values less than 1.9 mg/dL), Pyridorin™ did produce a treatment effect greater than 50% relative to placebo that is statistically significant. 

Patients treated with Pyridorin™ who were on previously established standard of care at screening, with a baseline SCr of up to 3 mg/dL, which includes patients with both mild and moderate levels of disease, showed a highly significant 57% treatment effect for the 300 mg arm (P = 0.009; n=64) and 45% for the 150 mg arm (P=0.045; n=62) relative to placebo. Pyridorin also slowed the progression of cystatin C and caused a reduction in urinary TGF beta in this patient population.

Approximately 70 to 80% of diabetic overt nephropathy patients have SCr values less than 2 mg/dL and approximately 80 to 90% have SCr values less than 3 mg/dL. Thus, Pyridor
'/>"/>

SOURCE NephroGenex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 ... CSL Behring its 2015 Corporate Leadership Award as ... science and improving the care of the bleeding disorders community.  ... and Managing Director, CSL Limited, during the NHF Annual Spring ... May 21. "The National Hemophilia Foundation is dedicated ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... “It’s like learning an new ... Vice President of Clinical Operations/Education and Training at ... impacts how care is coded and reimbursed.” , ... care reimbursement, operations and compliance consulting, as well ... launches a new series of day-long seminars on ...
(Date:5/22/2015)... Carnegie Science Center and ... partnership to develop BodyTech, a dynamic, three-pronged health and ... a new exhibit at the Science Center called BodyWorks, ... new traveling science show, Anatomy Adventure, which will hit ... Designed to explore a wide range of topics surrounding ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning ... some tips to help promote safe travel. , According to ... traffic fatalities this Memorial Day weekend. Amica is sharing the ... Association: , , Always wear a ... seatbelt, whether they’re driving or riding along as a passenger. ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... Poor sleep tied to quality of life, depression, study says ... common among elderly people who live in assisted living facilities, ... associated with declining quality of life and increased depression. , ... when they,re no longer able to live independently but do ...
... while longer-term risks are uncertain , FRIDAY, May 7 ... Gulf of Mexico and now some barrier islands off ... environment while posing risks to public health, experts say. ... headaches, nausea, coughing and throat irritation, according to the ...
... from a corticosteroid regimen have fewer cardiovascular events ... survival rates and reducing early mortality, according to ... of Cincinnati (UC) transplantation researchers. Researchers with ... medicine are presenting the work at the American ...
... explain different outcomes for women with similar-looking tumors, expert ... of breast cancer into subtypes can be achieved through ... U.S. researchers say. , They analyzed 32 gene expression ... and six classification models. , "We studied these models ...
... breast cancer , C.B. Agborsangaya, FINLAND, As women ... the incidence of pregnancy-associated breast cancer is expected ... p53 autoantibody-positive pregnant women may be useful in ... cancer. Abstract 92P: Post traumatic stress disorder ...
... a benign tumor of mesenchymal origin which is mostly ... 2/3 of small bowel occlusion caused by up to ... frequent benign tumor that causes invagination in its submucous ... form. However, multiple lipomas within the intestinal duplication canal ...
Cached Medicine News:Health News:Sleepless Nights Plague Assisted Living Residents 2Health News:Gulf Oil Spill Could Threaten Human Health 2Health News:Gulf Oil Spill Could Threaten Human Health 3Health News:Study finds post-transplant patients off steroids have fewer cardiovascular events 2Health News:Study finds post-transplant patients off steroids have fewer cardiovascular events 3Health News:Simple Test May Identify Breast Cancer Subtypes 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 3
... its synthetic bone substitute Ossatura. Developed at Isotis, ... material, i.e. a material that is designed to ... the musculo-skeletal system that results in bone growth. ... and reduces in part or entirely the need ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Daubenspeck sharp curette, 8....
Medicine Products: